Post by tchalaa on Apr 11, 2015 8:52:19 GMT -5
Attachment Deleted
From the "Form 10-Q, For the quarterly period ended June 30, 2014"
Under the terms of the Sanofi License Agreement, we granted to Sanofi a right of first negotiation in the event we propose to grant to any third party a license
to develop or exploit an inhaled glucagon-like peptide-1 agonist. In addition, if our board of directors determines to pursue a change of control of
MannKind, we will be required notify Sanofi of such determination within a certain period of time so that Sanofi may, at is discretion, negotiate with us for a
potential acquisition of MannKind by Sanofi.
From "INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION"
Change of Control Agreements
We have entered into change of control agreements with Messrs. Edstrom and Pfeffer, and Drs. Martens and Thomson. Each agreement is for a period of
two years and will be automatically renewed for additional one-year periods unless either party gives notice to terminate the agreement at least 90 days prior
to the end of its initial term or any subsequent term.
Under the agreements, a change of control will be deemed to occur upon:
• any transaction that results in a person or group acquiring beneficial ownership of 50% or more of our voting stock, other than us, one of our
employee benefit plans, Mr. Mann or any other entity in which Mr. Mann holds a majority of the beneficial interests;
• any merger, consolidation or reorganization of us in which our stockholders immediately prior to the transaction hold less than 50% of the
voting power of the surviving entity following the transaction, subject to certain limitations;
• any transaction in which we sell all or substantially all of our assets, subject to certain limitations;
• our liquidation; or
• any reorganization of our Board of Directors in which our incumbent directors (as defined in the agreements) cease for any reason to constitute a
majority of the members of our Board.
Questions:
Do you think that by the end of the 2Q'15 we'll have a BO or before November 2017 (due to COT) or latest in 3 years?
From the "Form 10-Q, For the quarterly period ended June 30, 2014"
Under the terms of the Sanofi License Agreement, we granted to Sanofi a right of first negotiation in the event we propose to grant to any third party a license
to develop or exploit an inhaled glucagon-like peptide-1 agonist. In addition, if our board of directors determines to pursue a change of control of
MannKind, we will be required notify Sanofi of such determination within a certain period of time so that Sanofi may, at is discretion, negotiate with us for a
potential acquisition of MannKind by Sanofi.
From "INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION"
Change of Control Agreements
We have entered into change of control agreements with Messrs. Edstrom and Pfeffer, and Drs. Martens and Thomson. Each agreement is for a period of
two years and will be automatically renewed for additional one-year periods unless either party gives notice to terminate the agreement at least 90 days prior
to the end of its initial term or any subsequent term.
Under the agreements, a change of control will be deemed to occur upon:
• any transaction that results in a person or group acquiring beneficial ownership of 50% or more of our voting stock, other than us, one of our
employee benefit plans, Mr. Mann or any other entity in which Mr. Mann holds a majority of the beneficial interests;
• any merger, consolidation or reorganization of us in which our stockholders immediately prior to the transaction hold less than 50% of the
voting power of the surviving entity following the transaction, subject to certain limitations;
• any transaction in which we sell all or substantially all of our assets, subject to certain limitations;
• our liquidation; or
• any reorganization of our Board of Directors in which our incumbent directors (as defined in the agreements) cease for any reason to constitute a
majority of the members of our Board.
Questions:
Do you think that by the end of the 2Q'15 we'll have a BO or before November 2017 (due to COT) or latest in 3 years?
